Loading…

Stratec SESBS.DECompetitor analysis, valuation and peers

Germany · EUR·Health Care›Medical Specialties
Momentum leader 100
Mkt cap
$365M
US dollars, full cap
Free float
62%
of shares outstanding
$/day
$605,948
20-day average traded
Fwd P/E
18.2×
forward earnings
ROIC−WACC
-4.9 pp
WACC 7.0%
Hurdle
+19 pp
Req g minus delivered
Next earnings
133 days
31 Mar 2027
Close · EUR€27.35
1D+1.1%
1W+4.6%
1M+21.6%
3M+26.3%
6M+62.8%
YTD+21.8%
1Y+35.7%
ATR %3.8%
52w lowhigh4.5% off high

What Stratec does

Employees: 1,403

Stratec at a glance

Size Stratec (SBS.DE) is a Germany Health Care company (Medical Specialties) with a market value of $365M, the 188th largest of 198 Germany companies the cockpit tracks. Shares closed at €27.35 on 18 Nov 2026.

Performance Over six months the shares gained 62.8%, against -15.0% for the median peer and -0.9% for the Germany market (cap-weighted) — 3rd highest of 20 in its peer set.

Growth Revenue fell 6.2% over the last twelve months (peer median +10.5%); the operating margin is 3.5% (peer median 12.2%).

Valuation It trades at 18.2× forward earnings against a peer median of 17.5× (6th most expensive of 12).

Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.9 points below its cost of capital (7.0% WACC).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012515021 May 202621 Aug 202618 Nov 2026SBS.DE 164Peer median 85
Six months, rebased to 100: Stratec against the median of its 20 peers (local-currency closes).

Stratec financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€240M€251M€258M€270M€275M
Revenue growth—-3%-5%-2%—
Gross profit€62.8M€64.2M€76.4M€68.2M€79.5M
EBITDA€54.3M€27.2M€44.9M€45.8M€58.9M
Net income-€42.4M-€242,000€16.0M€15.4M€29.2M
Free cash flow€34.6M-€9.71M€38.8M€11.0M-€18,000
Capital expenditure€12.2M€16.2M€18.2M€17.3M€19.0M
Total debt€110M€132M€131M€142M€87.1M

Quarterly statements and history in the cockpit →

Stratec competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-40%-20%0%+20%1609CV688338BWAY3005626748VBSN605186041830EMBCYDES458870CLTN688273SBS.DE6-month return →1-month return →
Up and to the right = strong over both horizons. Stratec is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%10×20×30×688338BWAY300562300653605186041830EMBC458870CLTN6929688273SBS.DERevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Stratec is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%1609688338BWAY300562VBSNEMBC458870688273SBS.DEGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Stratec is the large dot.

Stratec competitors and peer comparison

How Stratec compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Stratec against its 20 peers (data as of 18 Nov 2026)
MeasureSBS.DEPeer medianRank in peer set
1-month return+21.6%-12.0%highest of 21
6-month return+62.8%-15.0%3rd highest of 20
Distance from 52-week high-4.5%-44.8%highest of 21
Revenue growth (TTM)-6.2%+10.5%5th lowest of 21
Operating margin3.5%12.2%7th lowest of 21
Forward P/E18.2×17.5×6th most expensive of 12
Growth the price implies (Req g, 7 yrs)19.1%-5.3%3rd most demanding of 15
Growth delivered (Del g)+0.1%+4.8%6th lowest of 15
Hurdle (Req g minus delivered)+19.0 pp-2.0 pp2nd most demanding of 15
ROIC minus cost of capital-4.9 pp+8.5 pp6th lowest of 19
EV / EBITDA7.8×10.6×5th cheapest of 13
Net debt / EBITDA1.6×-2.8×3rd most indebted of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Stratec SBS.DEGermany$365M+63%-6%4%18.2×19.1%+0.1%
Star Sports Medicine 1609.HKHong Kong$364M-73%+23%37%n/a-13.1%+36.8%
CapsoVision CVUnited States$366M+5%+15%-213%n/an/an/a
Beijing Succeeder Technology 688338.SSChina$362M-18%-4%31%16.4×5.7%+3.4%
Brainsway Ltd Sponsored ADR BWAYUnited States$373M-41%+32%14%20.3×24.9%+18.8%
Guangdong Transtek Medical Electronics 300562.SZChina$373M-15%+7%11%25.3×-4.2%-6.0%
Yantai Zhenghai Bio-Tech 300653.SZChina$354M-23%-8%17%36.0×18.4%+4.4%
ACRO Biomedical 6748.TWOTaiwan$377M+158%+45%-178%n/an/an/a
Medcaptain Medical Technology 2041.HKHong Kong$378Mn/a+19%2%n/a17.1%+18.1%
IVF HARTMANN VBSN.SWSwitzerland$352M-2%+7%14%n/a-12.7%-1.3%
Shanghai General Healthy Information & Technology 605186.SSChina$379M-26%-11%5%37.2×n/an/a
InBody 041830.KSSouth Korea$380M-13%+22%22%11.3×-10.3%+16.9%
Embecta EMBCUnited States$345M+99%-8%26%3.8×-19.9%-0.1%
Taidoc Technology 4736.TWTaiwan$387M0%0%19%n/a-9.5%-6.6%
YD Bio YDESUnited States$344M+7%+17%-883%n/an/an/a
Shanghai Kehua Bio-Engineering 002022.SZChina$389M-14%+7%-40%n/an/an/a
Cerus CERSUnited States$392M-28%+14%-12%n/an/an/a
SEERS 458870.KSSouth Korea$392M-70%+174%37%15.2×-6.3%+247.0%
COLTENE CLTN.SWSwitzerland$339M-7%-2%8%25.2×-0.3%-0.7%
OrbusNeich Medical 6929.HKHong Kong$394M-15%+16%23%8.4×-17.6%+15.4%
Nanjing Medlander Medical Technology 688273.SSChina$337M-47%-12%8%17.5×35.3%+5.2%

Questions

Which companies are Stratec's closest peers?
The cockpit's peer set: Star Sports Medicine (1609.HK), CapsoVision (CV), Beijing Succeeder Technology (688338.SS), Brainsway Ltd Sponsored ADR (BWAY), Guangdong Transtek Medical Electronics (300562.SZ), Yantai Zhenghai Bio-Tech (300653.SZ), ACRO Biomedical (6748.TWO), Medcaptain Medical Technology (2041.HK).
Is Stratec expensive compared with its peers?
On forward p/e it trades at 18.2× against a peer median of 17.5×, 6th most expensive of 12 in its peer set. For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Stratec stock performed?
Over six months to 18 Nov 2026 the shares returned +62.8% against -15.0% for the median peer; over one year +35.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.